Quercis Pharma

Focus: Quercis Pharma is a Swiss-based small molecule company focused on rare diseases and infectious diseases with a lean pipeline in clinical development. The company is publicly listed but operates at modest scale with minimal commercial revenue.

Rare Diseases Infectious Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Quercis Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Quercis Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Isoquercetin

Sickle Cell Disease

Phase 2

Clinical Trials (1)

NCT04514510Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Phase 2

Help build intelligence for Quercis Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to three active clinical programs across high-impact indications (sickle cell disease, venous thromboembolism, COVID-19)
Rare disease and infectious disease focus offers meaningful therapeutic impact and regulatory advantages
Swiss headquarters provides stable governance and access to European talent pool and regulatory pathways

Watch Out For

Zero open job postings signals limited hiring activity or organizational constraints
Pre-revenue or minimal revenue status creates cash runway and sustainability uncertainty
Only three clinical trials across entire pipeline suggests narrow resource allocation and high development concentration risk

Generated by Claude from Quercis Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Isoquercetin

COVID-19

Phase 2

Clinical Trials (1)

NCT04536090Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Phase 2

Kinisoquin™

Venous Thromboembolism

Phase 3

Clinical Trials (1)

NCT06861088The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase 3